- Home
- COGT vs GDRX Comparison
COGT vs GDRX Comparison
Compare COGT & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- GDRX
- Stock Information
- Founded
- COGT 2014
- GDRX 2011
- Country
- COGT United States
- GDRX United States
- Employees
- COGT N/A
- GDRX N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- GDRX Retail: Computer Software & Peripheral Equipment
- Sector
- COGT Health Care
- GDRX Technology
- Exchange
- COGT Nasdaq
- GDRX Nasdaq
- Market Cap
- COGT 1.1B
- GDRX 1.2B
- IPO Year
- COGT 2018
- GDRX 2020
- Fundamental
- Price
- COGT $13.05
- GDRX $4.00
- Analyst Decision
- COGT Strong Buy
- GDRX Buy
- Analyst Count
- COGT 11
- GDRX 8
- Target Price
- COGT $21.20
- GDRX $5.88
- AVG Volume (30 Days)
- COGT 1.2M
- GDRX 6.0M
- Earning Date
- COGT 08-05-2025
- GDRX 08-06-2025
- Dividend Yield
- COGT N/A
- GDRX N/A
- EPS Growth
- COGT N/A
- GDRX N/A
- EPS
- COGT N/A
- GDRX 0.09
- Revenue
- COGT N/A
- GDRX $799,874,000.00
- Revenue This Year
- COGT N/A
- GDRX $2.82
- Revenue Next Year
- COGT N/A
- GDRX $5.31
- P/E Ratio
- COGT N/A
- GDRX $44.85
- Revenue Growth
- COGT N/A
- GDRX 3.20
- 52 Week Low
- COGT $3.72
- GDRX $3.31
- 52 Week High
- COGT $13.50
- GDRX $8.15
- Technical
- Relative Strength Index (RSI)
- COGT 66.38
- GDRX 42.45
- Support Level
- COGT $11.87
- GDRX $4.21
- Resistance Level
- COGT $13.50
- GDRX $4.56
- Average True Range (ATR)
- COGT 0.55
- GDRX 0.31
- MACD
- COGT 0.05
- GDRX -0.00
- Stochastic Oscillator
- COGT 77.16
- GDRX 1.05
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About GDRX GoodRx Holdings Inc.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.